In a phase 1, first-in-human study (FIHS) (NCT01777243; GSK study identifier SAP115570) the efficacy and safety of up to 3 cycles of treatment with miridesap and dezamizumab were assessed in patients with AL, AA, ATTR, AFib and ApoAI amyloidosis [16, 17]. The gene discussed is TTR; the disease is amyloidosis.